louisiana glp-1 gi obstruction attorney law firm in semaglutide gastric intestinal semaglutide digestive blockage louisiana semaglutide obstruction lawyer in louisiana Louisiana Diabetes Drugs & Gastrointestinal Injuries GLP -1 Lawsuit louisiana glp-1 gastric intestinal obstruction

"Paradigm shift in obesity treatment: an extensive review of current pipeline agents." 2025

Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones

Influencers post dramatic before-and-after photos

Restrictions continue to rise for many GIP and GLP-1 medications: In 2025, over 82% of people with insurance plans that offer coverage for Wegovy, Zepbound, and Saxenda will encounter restrictions, like prior authorization or step therapy, that make access difficult

The hazard ratios for the full follow-up period in these analyses was 1.37 (95% confidence interval 0.84 to 2.23), 1.04 (0.69 to 1.57), and 0.99 (0.67 to 1.46), respectively

However, the strength of effects, ideal dosing, and long-term outcomes are not fully established for general consumer use, and clinical standards vary by region